Impact of Abdominal Incompetence on Urinary Incontinence After Prostatectomy (PROSTABDO)
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON · Jun 20, 2022
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Impact of Abdominal Incompetence on Urinary Incontinence After Prostatectomy" (PROSTABDO) is studying how the strength of the abdominal muscles affects urinary control in men after surgery for prostate cancer. Researchers will use ultrasound to examine the abdominal muscles of participants before they undergo robotic-assisted prostate surgery. They want to find out if men who experience urinary incontinence one year after surgery had signs of weak abdominal muscles before their operation.
To participate in this study, you must be a male with prostate cancer who is scheduled for a robotic-assisted laparoscopic radical prostatectomy. However, if you have had urinary incontinence before the surgery, neurological conditions that affect bladder function, or previous surgery for an abdominal wall hernia, you will not be eligible. If you join the trial, you can expect to have a brief ultrasound of your abdominal muscles before your surgery, and then follow-up assessments one year later to see how you are doing with urinary control. This research aims to improve understanding of how abdominal muscle function relates to urinary issues after prostate surgery, which could help guide future treatments and support for patients.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • male with prostate cancer going to have a robotic-assisted laparoscopic radical prostatectomy
- Exclusion Criteria:
- • neurological patology with bladder impact (SCI, parkinson disease, multiple sclerosis....)
- • urinary incontinence before surgery
- • surgery for abdominal wallhernia
About Centre Hospitalier Universitaire De Besancon
The Centre Hospitalier Universitaire de Besançon (CHU de Besançon) is a leading academic medical center located in Besançon, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Besançon focuses on a wide range of medical disciplines, fostering collaboration between healthcare professionals and researchers to develop new therapeutic strategies and improve patient outcomes. With a commitment to rigorous scientific standards and ethical practices, the institution plays a vital role in translating research findings into practical applications, ultimately enhancing the quality of care provided to the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Besançon, , France
Patients applied
Trial Officials
Emilie CERUTTI
Principal Investigator
University hospital of Besançon
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials